Intellia Therapeutics Presents Nex-z Clinical Data at AHA and ISA Meetings
Bitget2026/11/03 13:05- Intellia Therapeutics will present Phase 1 nex-z data at American Heart Association Scientific Sessions in Chicago, Nov. 6-9, 2026.
- The Nov. 9 presentation will highlight cardiac outcomes following a single dose in hereditary transthyretin amyloidosis patients with polyneuropathy and cardiac involvement.
- A Nov. 18 presentation will cover up to four years of follow-up in patients with hereditary transthyretin amyloidosis with polyneuropathy.
- That presentation is scheduled for the International Society of Amyloidosis symposium, held Nov. 15-18, 2026, in Montevideo, Uruguay.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
